High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register

Clinical Rheumatology

Volumn 33, Issue 1, 2014, Pages 31-37

  Iannone, Florenzo ^a   Gremese, Elisa ^b   Gallo, Gaia ^c   Sarzi Puttini, Piercarlo ^d   Botsios, Costantino ^e   Trotta, Francesco ^f   Gasperini, Stefania ^g   Galeazzi, Mauro ^h   Adami, Silvano ⁱ   Cantini, Fabrizio ^j   Sebastiani, Marco ^k   Gorla, Roberto ^l   Marchesoni, Antonio ^m   Giardina, Annarita ⁿ   Foti, Rosario ^o   Mele, Angiola ^p   Bruschi, Eleonora ^q   Bagnato, Gianluca ^r   Erre, Gian Luca ^s   Lapadula, Giovanni ^a   Scioscia, Crescenzio ^t   Fedele, Anna Laura ^t   Ferraccioli, Gianfranco ^t   Atzeni, Fabiola ^t   Bongiovanni, Sara ^t   Punzi, Leonardo ^t   Bernardi, Livio ^t   Bagnari, Valentina ^t   Govoni, Marcello ^t   Grassi, Walter ^t   Salaffi, Fausto ^t   Manganelli, Stefania ^t   Frati, Elena ^t   Carletto, Antonio ^t   Caimmi, Cristian ^t   Palloni, Alice ^t   Niccoli, Laura ^t   Ferri, Clodoveo ^t   Favalli, Ennio Giulio ^t   Triolo, Giovanni ^t   Di Gangi, Marcella ^t   more..

^a POLICLINICO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SRL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Paediatric Rheumatology Unit Department of Paediatrics   (Italy)

^f Rheumatology Unit   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j MISERICORDIA E DOLCE HOSPITAL   (Italy)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^l Rheumatology Unit   (Italy)

^m ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o UNIVERSITY OF CATANIA   (Italy)

^p UNIVERSITY OF FOGGIA   (Italy)

^q OSPEDALE NIGUARDA CA GRANDA   (Italy)

^r Rheumatology Unit   (Italy)

^s Rheumatology Unit   (Italy)

^t Gruppo Italiano di Studio Sulle Early Arthritides (GISEA)   (Italy)

more..

Author keywords

DAS28; Disease remission; GISEA; HAQ; TNF inhibitors

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT;

ARTICLE; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE DURATION; HEALTH ASSESSMENT QUESTIONNAIRE; MEDICAL SOCIETY; PRIORITY JOURNAL; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; ITALY; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84897631607     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2348-6     Document Type: Article

References (20)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631-637
2. Aletaha D, Smolen JS (2006) The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 32:9-44, vii
3. Saraux A, Gossec L, Goupille P, Bregman B, Boccard E, Dupont D, Beresniak A (2010) Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 49:733-740
4. Conaghan PG, Hensor EMA, Keenan AM, Morgan AW, Emery P (2010) Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology 49:1894-1899
5. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T et al (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 8:R66
6. Keystone E, Freundlich B, Schiff M, Li J, Hooper M (2009) Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol 36:522-531
7. Hyrich KL, Deighton C, Watson KD, BSRBR Control Centre Consortium, Symmons DP, Lunt M, British Society for Rheumatology Biologics Register (2009) Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 48:1323-1327
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
9. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
10. van Gestel AM, PrevooML, van Hof MA, van RijswijkMH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34-40
11. Valesini G, Montecucco C, Cutolo M (2006) Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24:413-423
12. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625-639
13. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann RheumDis 69:964-975
14. Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit Working Group (2005) Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44:157-163
15. Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R et al (2010) BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) 49:1197-1199
16. Kiely P, Walsh D, Williams R, Young A, Network ERA (2011) Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN). Rheumatology (Oxford) 50:926-931
17. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P et al (2012) Long-term retention of tumor necrosis factor-a inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39:1179-1184
18. Bansback NJ, Brennan A, Ghatnekar O (2005) Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 64:995-1002
19. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P et al (2006) Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 45:1029-1038
20. Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G (2002) Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 29:1847-1850